SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells.

Daniel J O'Neill, Stuart Charles Williamson, Dhuha Alkharaif, Isabella Christina Mazzaro Monteiro, Marilyn Goudreault, Luke Gaughan, Craig N Robson, Anne-Claude Gingras, Olivier Binda

Index: Epigenetics 9(7) , 942-50, (2014)

Full Text: HTML

Abstract

The lysine methyltransferase SETD6 modifies the histone variant H2AZ, a key component of nuclear receptor-dependent transcription. Herein, we report the identification of several factors that associate with SETD6 and are implicated in nuclear hormone receptor signaling. Specifically, SETD6 associates with the estrogen receptor α (ERα), histone deacetylase HDAC1, metastasis protein MTA2, and the transcriptional co-activator TRRAP. Luciferase reporter assays identify SETD6 as a transcriptional repressor, in agreement with its association with HDAC1 and MTA2. However, SETD6 behaves as a co-activator of several estrogen-responsive genes, such as PGR and TFF1. Consistent with these results, silencing of SETD6 in several breast carcinoma cell lines induced cellular proliferation defects accompanied by enhanced expression of the cell cycle inhibitor CDKN1A and induction of apoptosis. Herein, we have identified several chromatin proteins that associate with SETD6 and described SETD6 as an essential factor for nuclear receptor signaling and cellular proliferation.